Q-omics provides the consensus-scored SP6 profile across patient tissues and cancer cell-line models. SP6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SP6 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SP6 RNA expression shows 15,913 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, COAD, and THYM as cancer lineages where SP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP6 survival associations across molecular data types. SP6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP6 RNA expression–survival associations across cancer types. High SP6 expression shows unfavorable associations in LUSC, ACC, BRCA, LUAD and LGG, but favorable associations in BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SP6 RNA expression.
This table summarizes SP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP6 shows higher tumor expression in COAD, LIHC, BRCA, READ, PAAD and STAD. The COAD box plot shows higher SP6 RNA expression in tumor versus normal tissue (log2 FC = +2.007, t-test p < 0.001).
This table shows molecular features associated with SP6 in patient tissues and cancer cell lines. In patient samples, SP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
